1233855-46-3 Usage
Description
BIA10-2474, also known as N-Cyclohexyl-N-methyl-4-(1-oxido-3-pyridinyl)-1H-imidazole-1-carboxamide, is a potential fatty acid amide hydrolase (FAAH) inhibitor. It is a synthetic compound designed to target and inhibit the FAAH enzyme, which is involved in the degradation of endocannabinoids, such as anandamide. By inhibiting FAAH, BIA10-2474 can increase the levels of endocannabinoids in the body, potentially leading to therapeutic benefits in various conditions.
Uses
Used in Pharmaceutical Industry:
BIA10-2474 is used as a potential therapeutic agent for treating and preventing diseases. Its ability to inhibit FAAH and increase endocannabinoid levels makes it a promising candidate for the treatment of various conditions, such as pain, inflammation, anxiety, and neurodegenerative disorders. The modulation of the endocannabinoid system by BIA10-2474 may provide a novel approach to managing these diseases and improving patient outcomes.
Additionally, BIA10-2474's potential applications may extend to other industries, such as cosmetics or dietary supplements, where the modulation of the endocannabinoid system could offer benefits for skin health, stress relief, or other wellness-related purposes. However, further research and clinical trials are necessary to fully understand the safety, efficacy, and appropriate uses of BIA10-2474 in these contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 1233855-46-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,3,8,5 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1233855-46:
(9*1)+(8*2)+(7*3)+(6*3)+(5*8)+(4*5)+(3*5)+(2*4)+(1*6)=153
153 % 10 = 3
So 1233855-46-3 is a valid CAS Registry Number.
1233855-46-3Relevant articles and documents
Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase
Kiss, László E.,Beliaev, Alexandre,Ferreira, Humberto S.,Rosa, Carla P.,Bonifácio, Maria Jo?o,Loureiro, Ana I.,Pires, Nuno M.,Palma, P. Nuno,Soares-da-Silva, Patrício
, p. 2177 - 2188 (2018/09/25)
Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain associated with various medical conditions. Herein we report the design and synthesis of a novel series of heterocyclic-N-carboxamide FAAH inhibitors that have a good alignment of potency, metabolic stability and selectivity for FAAH over monoacylglycerol lipase (MAGL) and carboxylesterases (CEs). Lead optimization efforts carried out with benzotriazolyl- and imidazolyl-N-carboxamide series led to the discovery of clinical candidate 8 l (3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide; BIA 10-2474) as a potent and long-acting inhibitor of FAAH. However, during a Phase I clinical trial with compound 8 l, unexpected and unpredictable serious neurological adverse events occurred, affecting five healthy volunteers, including the death of one subject.
PHARMACEUTICAL COMPOUNDS
-
, (2012/03/27)
The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to subs
